Biohit Oyj - Changes board/management/auditors

CHANGES IN BIOHIT OYJ'S DIAGNOSTICS MANAGEMENT TEAM

BIOHIT OYJ STOCK EXCHANGE RELEASE ON 30 SEPTEMBER 2010 AT 2:00 PM               

CHANGES IN BIOHIT OYJ'S DIAGNOSTICS MANAGEMENT TEAM                             

The Diagnostics Management Team of Biohit Oyj will be reorganized in line with  
the new strategy of the Group. The change comes into effect on October 1st 2010.

In addition to the Group's President & CEO, Mr Jussi Heiniö and the General     
Director of Diagnostics, Mr Yrjö Wichmann, the new Management Team will include 
the following members and functions: Ms Lea Paloheimo (Product Portfolio        
Management); Mr Kalle Härkönen (Operations); Ms Terhi Lampén (Sales and         
Marketing); Mr Seppo Riikonen (Quality and Risk Management); Ms Tiina Hankonen  
(Finance, ICT and HR); and Ms Josefin Hoviniemi (Communications).               

The reform reflects the new approach to make the business planning and          
operations more efficient and develop the company's business in a truly         
international direction, by utilising the Group's own resources and large       
network of subsidiaries.                                                        

Biohit has two Management Teams. The Diagnostics Management Team focuses on the 
diagnostics business and its development, while the Liquid Handling Management  
Team focuses on the liquid handling business and its development, as well as    
Group-level administration. The Liquid Handling Management Team was reorganized 
in beginning of July this year.                                                 


Jussi Heiniö                                                                    
President & CEO                                                                 
Biohit Oyj                                                                      


Further information:                                                            
Jussi Heiniö                                                                    
Tel: +358-9-773 861                                                             
Email: jussi.heinio@biohit.com                                                  

Distribution:                                                                   
NASDAQ OMX Helsinki Oy                                                          
Central storage facility (www.oam.fi)                                           
Press                                                                           
www.biohit.com                                                                  


About Biohit Oyj                                                                

Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on   
the global market. Biohit's operations are based on a goal-oriented and         
long-term innovation and patenting strategy.                                    
Biohit works with scientific communities to produce new technologies, products  
and services based on research results and innovations that can be used to      
develop safe and cost-effective liquid handling solutions for laboratory work as
well as diagnostic tests for the early detection and prevention of diseases of  
the gastrointestinal tract.                                                     

Biohit has two business segments: liquid handling and diagnostics. Liquid       
handling products include electronic and mechanical pipettes, disposable tips as
well as pipette maintenance and calibration services for research institutions, 
healthcare and industrial laboratories.                                         

The diagnostics business comprises products and analysis systems for the early  
diagnosis of gastrointestinal diseases, such as the blood-sample based          
GastroPanel examinations for the diagnosis of stomach illnesses and associated  
risks, quick tests for the diagnosis of lactose intolerance and H. pylori       
infection in connection with gastroscopy, and the ColonView examination for the 
early detection of intestinal bleeding that indicates a risk of colorectal      
cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic    
stomachs.                                                                       

The Biohit Group employs around 390 people. The company is headquartered in     
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,     
India, China, Japan and the USA, as well as a representative office in          
Singapore. Additionally, Biohit's products are sold by approximately 450        
distributors in 70 countries.                                                   

Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small         
cap/Healthcare since 1999.                                                      

Read more at www.biohit.com